Last reviewed · How we verify
Roche — Portfolio Competitive Intelligence Brief
RHHBY (OTC)
52 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Itovebi | INAVOLISIB | marketed | Kinase Inhibitor [EPC] | Oncology | 2025-01-01 | |
| Piasky | CROVALIMAB | marketed | Complement C5 Inhibitor [EPC] | Immunology | 2025-01-01 | |
| Xofluza | BALOXAVIR | marketed | Infectious Disease | 2025-01-01 | ||
| Columvi | glofitamab | marketed | Bispecific CD20-directed CD3 T Cell Engager [EPC] | B-lymphocyte antigen CD20 | Oncology | 2023-01-01 |
| Vabysmo | FARICIMAB | marketed | Vascular endothelial growth factor A | Metabolic | 2022-01-01 | |
| Lunsumio | MOSUNETUZUMAB | marketed | B-lymphocyte antigen CD20 | Oncology | 2022-01-01 | |
| Evrysdi | RISDIPLAM | marketed | Survival of Motor Neuron 2 Splicing Modifier [EPC] | Neuroscience | 2020-01-01 | |
| Polivy | POLATUZUMAB VEDOTIN | marketed | B-cell antigen receptor complex-associated protein beta chain | Oncology | 2019-01-01 | |
| Rozlytrek | entrectinib | marketed | High affinity nerve growth factor receptor | Oncology | 2019-01-01 | |
| Xofluza | BALOXAVIR MARBOXIL | marketed | Infectious Disease | 2018-01-01 | ||
| Hemlibra | EMICIZUMAB | marketed | Coagulation factor IX | Hematology | 2017-01-01 | |
| Ocrevus | OCRELIZUMAB | marketed | CD20-directed Cytolytic Antibody [EPC] | B-lymphocyte antigen CD20 | Neuroscience | 2017-01-01 |
Therapeutic area mix
- Oncology · 25
- Immunology · 8
- Neuroscience · 4
- Infectious Disease · 3
- Metabolic · 3
- Cardiovascular · 2
- Hematology · 2
- Other · 2
- Rare Disease · 1
- Pain · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Cytovene · 9486530 · Formulation · US
- — Cellcept · 12194143 · Formulation · US
- — Cellcept · 12097285 · Formulation · US
- — Cellcept · 12226526 · Formulation · US
- — Cellcept · 11931455 · Formulation · US
- — Cellcept · 12097284 · Formulation · US
Competitive overlap (companies sharing drug classes)
- · 8 shared drug classes
- Pfizer · 5 shared drug classes
- Sanofi · 5 shared drug classes
- Novartis · 4 shared drug classes
- Amgen · 4 shared drug classes
- Bayer · 3 shared drug classes
- AMGEN INC · 3 shared drug classes
- Boehringer Ingelheim · 3 shared drug classes
Subscribe to ongoing alerts
Every new pipeline event for Roche:
Cite this brief
Drug Landscape (2026). Roche — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/roche. Accessed 2026-05-13.